Matches in Wikidata for { <http://www.wikidata.org/entity/Q90610295> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- Q90610295 description "2020 թվականին հրատարակված գիտական հոդված" @default.
- Q90610295 description "article scientifique (publié 2020)" @default.
- Q90610295 description "articolo scientifico (pubblicato il 2020)" @default.
- Q90610295 description "artigo científico (publicado na 2020)" @default.
- Q90610295 description "artikull shkencor i botuar më 01 janar 2020" @default.
- Q90610295 description "artículo científico publicado en 2020" @default.
- Q90610295 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q90610295 description "im Jahr 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90610295 description "scientific article published on 01 January 2020" @default.
- Q90610295 description "wetenschappelijk artikel" @default.
- Q90610295 description "наукова стаття, опублікована 1 січня 2020" @default.
- Q90610295 description "научна статия" @default.
- Q90610295 name "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 name "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 name "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 type Item @default.
- Q90610295 label "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 label "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 label "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 prefLabel "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 prefLabel "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 prefLabel "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 P1433 Q90610295-82A01FF8-7801-4649-A05B-20BD2BC05358 @default.
- Q90610295 P1476 Q90610295-8A813488-DCB6-4DA6-9FBF-980B55D43ECE @default.
- Q90610295 P2093 Q90610295-06888548-3C15-4D25-99A2-FB94A35D9A41 @default.
- Q90610295 P2093 Q90610295-454D2BE1-BD86-49E4-A29C-7D97A9348228 @default.
- Q90610295 P2093 Q90610295-652013E4-FBF1-4970-B648-21E28EF56F58 @default.
- Q90610295 P2093 Q90610295-8699C9EE-5981-48F6-B235-27EB0C1CE036 @default.
- Q90610295 P2093 Q90610295-F2C73441-6B8C-4F0F-B956-D67EBB650278 @default.
- Q90610295 P275 Q90610295-EFDCB872-6DF7-41ED-B6BD-7F88E3252C36 @default.
- Q90610295 P2860 Q90610295-1F8624C8-4C37-453D-A7B4-1D8746E4DB65 @default.
- Q90610295 P2860 Q90610295-21799E8A-E760-4969-8327-C3E5486B8A03 @default.
- Q90610295 P2860 Q90610295-33D166D0-F1AF-444F-8E45-11BEAC4205A5 @default.
- Q90610295 P2860 Q90610295-602FBDDA-B3D4-43E1-9A19-EC9406FDCBC9 @default.
- Q90610295 P2860 Q90610295-759FAF87-C768-4CF9-A6D9-52F50692B549 @default.
- Q90610295 P2860 Q90610295-9E0EA3C7-0AE8-4517-ACF9-2655832E69E6 @default.
- Q90610295 P2860 Q90610295-A241072E-33F1-4DD6-9DE1-F740BAEAF5C8 @default.
- Q90610295 P2860 Q90610295-B1F32C6D-65A1-44CF-AA42-BF11F04ED676 @default.
- Q90610295 P2860 Q90610295-CF2D4DFC-3D39-40C5-9513-7AC0F489EF35 @default.
- Q90610295 P304 Q90610295-05F5F48E-4464-4C01-8E00-29A5772DF258 @default.
- Q90610295 P31 Q90610295-9E108EC9-38BE-44AA-AE90-F51807C5BF94 @default.
- Q90610295 P356 Q90610295-7F68BC63-8F98-429D-A725-194C202C7BE2 @default.
- Q90610295 P433 Q90610295-0A920922-BE35-438C-BB8C-6889700D5B75 @default.
- Q90610295 P478 Q90610295-9CC1371B-5DBE-4B2F-B51A-0CBE3A30F9F9 @default.
- Q90610295 P50 Q90610295-3A81AC56-B1F7-4BE3-8E57-C73074C3167F @default.
- Q90610295 P577 Q90610295-E91A9966-07C5-4C07-9796-9C8C27C83A8C @default.
- Q90610295 P6216 Q90610295-51B9562C-9CC7-423A-90E9-FB286750185E @default.
- Q90610295 P698 Q90610295-E980E488-6297-4556-B8EB-AF15F9749C35 @default.
- Q90610295 P932 Q90610295-B81DD797-A314-4AAE-890B-479F70441FAC @default.
- Q90610295 P356 2055217320911939 @default.
- Q90610295 P698 32206332 @default.
- Q90610295 P1433 Q27726873 @default.
- Q90610295 P1476 "An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability" @default.
- Q90610295 P2093 "Ashish Pradhan" @default.
- Q90610295 P2093 "Clyde Markowitz" @default.
- Q90610295 P2093 "Edward J Fox" @default.
- Q90610295 P2093 "Jinglan Pei" @default.
- Q90610295 P2093 "Natalie J Engmann" @default.
- Q90610295 P275 Q34179348 @default.
- Q90610295 P2860 Q22241644 @default.
- Q90610295 P2860 Q37118141 @default.
- Q90610295 P2860 Q37776180 @default.
- Q90610295 P2860 Q38629185 @default.
- Q90610295 P2860 Q38758444 @default.
- Q90610295 P2860 Q40400256 @default.
- Q90610295 P2860 Q40400262 @default.
- Q90610295 P2860 Q44603931 @default.
- Q90610295 P2860 Q89172362 @default.
- Q90610295 P304 "2055217320911939" @default.
- Q90610295 P31 Q13442814 @default.
- Q90610295 P356 "10.1177/2055217320911939" @default.
- Q90610295 P433 "1" @default.
- Q90610295 P478 "6" @default.
- Q90610295 P50 Q90610290 @default.
- Q90610295 P577 "2020-01-01T00:00:00Z" @default.
- Q90610295 P6216 Q50423863 @default.
- Q90610295 P698 "32206332" @default.
- Q90610295 P932 "7079307" @default.